Meet the CIPHER grantees

Suvaporn Anugulruengkitt

Year awarded: 2015
Institution: Chulalongkorn University, Thailand
Research site: Department of Paediatrics, Faculty of Medicine, Chulalongkorn University
Primary mentor: Thanyawee Puthanakit, Department of Paediatrics, Chulalongkorn University, and HIVNAT, Thai Red Cross AIDS Research Centre

Suvaporn Anugulruengkitt is a lecturer in the Paediatric Infectious Diseases Unit, Department of Paediatrics, King Chulalongkorn Memorial Hospital. She has worked as a paediatric infectious specialist since 2014, with her clinical research focus on PMTCT and ART.

More information on Suvaporn | Email

“Due to the CIPHER grant, I had the opportunity to do this research as part of a PhD study. The funding also supports my participation at the IAS and AIDS conferences for three years, and that results in a great experience, both academically and for networking.”

Research project: Adverse events of 6-week zidovudine/lamivudine/nevirapine antiretroviral prophylaxis regimen for prevention of vertical transmission of HIV among high risk neonates in Thailand

The issue

UNAIDS has set the goal of elimination of perinatal HIV transmission by 2015. In Thailand, combination ART is offered to all pregnant women, and four weeks of zidovudine is offered to the neonate. However, if the mother is at high risk of HIV transmission to her child, then a six-week course of zidovudine/lamivudine/nevirapine is recommended for neonates. Theoretically, this regimen should provide good efficacy, but it may also pose more risk of adverse events.

The CIPHER project

The specific aims of this project were to:

  • Compare the incidence of adverse events, such as anaemia, neutropenia and hepatitis, of a six-week zidovudine/lamivudine/nevirapine neonatal prophylaxis regimen among HIV-exposed high-risk neonates and a control group of infants who received a four-week zidovudine regimen
  • Determine the HIV transmission rate among HIV-exposed high-risk neonates who received a triple-ARV regimen
  • Describe nevirapine concentration levels during the first four weeks of life among HIV-exposed neonates.

The impact

Before the research started, there were limited safety data of triple-ARV prophylaxis in high-risk neonates. Dr Anugulruengkitt’s research demonstrated that triple regimen with no lead-in NVP dosing 4mg/kg initiating at birth may apply in resource-limited settings to simplify regimens with adequate level of NVP for prophylaxis and without significant toxicity. Her team plans to share the data from the study with the Thailand MOPH-US CDC Collaboration and national health departments.